Personalized, or precision, medicine applied to cancer treatment has its origins in studies of human genetics and the genetic mutations found in different cancers. A variety of personalized treatments continue to make advances in increasing patients' longevity and quality of life.
A new study in the British Medical Journal suggests that the majority of new cancer drugs approved by the European Medicines Agency lacked evidence that they improved survival or the quality of life of patients.
Due to the opaque nature of the pharmaceutical industry’s disclosures, a study published in JAMA Internal Medicine sought to quantify a standard amount companies spent on the research and development of cancer drugs. Do these R&D costs justify such high prices and revenues?
Here s a simple question with nothing even close to a simple answer: Do cancer drugs cost too much? ACSH s Dr. Josh Bloom, who has written frequently on this subject, including an op-ed the New York Post thinks that al too often they are. He says, There are obvious cases of recently approved cancer drugs that offer very little benefit in terms of either disease-free progression or extension of life. The annual cost for these drugs is roughly $100,000, but
Ductal carcinoma in situ (DCIS) is the presence of abnormal cells inside a milk duct in the breast. DCIS is considered the earliest form of breast cancer, and is the most common type of non-invasive breast cancer. DCIS